Table 2 Demographics by trial.

From: Early treatment-related neutropenia predicts response to palbociclib

Trial

Basket Trial

Sarcoma Trial

Total patients

137

59

Tumour type, N (%)a

    Breast

61 (45%)

0 (0%)

    Liposarcoma

1 (<1%)

59 (100%)

    Germ cell

30 (22%)

0 (0%)

    Colorectal

22 (16%)

0 (0%)

    Oesophageal

12 (9%)

0 (0%)

    Otherb

11 (6%)

0 (0%)

Age in years, median (range)a

56 (17–88)

62 (35–87)

Gender, N (%)

    Female

80 (58%)

29 (49%)

    Male

57 (42%)

30 (51%)

Race, N (%)

    White

122 (89%)

47 (79%)

    Black

8 (6%)

4 (7%)

    Asian/other

7 (5%)

8 (14%)

BMI, median (range)c

25.8 (16.0–47.1)

27.2 (17.5–48.0)

Baseline ECOG PS, N (%)a

    0

71 (52%)

51 (86%)

    1

66 (48%)

8 (14%)

# Prior lines of therapy, N (%)a

    0

2 (1%)

22 (37%)

    1

23 (17%)

29 (49%)

    2

23 (17%)

4 (7%)

    ≥3

89 (65%)

4 (7%)

Immediate prior line chemotherapy, N (%)a

    Yes

38 (28%)

37 (63%)

    No

99 (72%)

22 (37%)

Baseline ANC (K/μL), median (range)

4.2 (1.5–31.9)

4.1 (1.5–10.2)

  1. aFisher’s Exact p < 0.05 (Wilcoxon rank-sum used for age, BMI, and baseline ANC).
  2. bOthers are diagnoses representing <5% of all patients (adrenal, gastric, glioblastoma, renal cell, and thymus cancers).
  3. cMissing BMI values for two patients in Basket Trial (due to unrecorded height).
Back to article page